Associate Professor of Medicine, Beth Israel Deaconess Medical Center
Pathology
Dr. Stan N. Finkelstein, MD
|
|
Give Review
Stan Finkelstein is an expert in the field of Pathology. He graduated from Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care Stan N. Finkelstein is a published doctor and has 42 publications published. The lastest was: 'Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia.'
Publications
- Disease-based Modeling to Predict Fluid Response in Intensive Care Units.
- Reducing unnecessary lab testing in the ICU with artificial intelligence.
- Missing data in medical databases: Impute, delete or classify?
- Vaccine availability in the United States during the 2009 H1N1 outbreak.
- Trends in the use and role of biomarkers in phase I oncology trials.
- Off-label prescribing among office-based physicians.
- The economic burden of anemia in cancer patients receiving chemotherapy.
- Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
- The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans.
- Costs of antidepressant medications associated with inadequate treatment.
- Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis.
- Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.
- Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter?
- A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998.
- National trends in asthma visits and asthma pharmacotherapy, 1978-2002.
- Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.
- National Patterns of Medication Treatment for Depression, 1987 to 2001.
- Blood policy revisited--a new look at "The Gift Relationship"
- Economic evaluation of a Bayesian model to predict late-phase success of new chemical entities.
- A framework to evaluate the economic impact of pharmacogenomics.
- Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety.
- The impact of treatment-resistant depression on health care utilization and costs.
- The economic burden of anxiety disorders in the 1990s.
- The economic burden of depression in 1990.
- The cost consequences of treatment-resistant depression.
- Loss of work productivity due to illness and medical treatment.
- Depression: a neglected major illness.
- Lost human capital from early-onset chronic depression.
- Performance decrements resulting from illness in the workplace: the effect of headaches.
- Health care use and at-work productivity among employees with mental disorders.
- A home toolkit for primary prevention of influenza by individuals and families.
- Controlling post-transfusion hepatitis: a proposal to publicize hepatitis rates of transfusion facilities.
- When antihistamines go to work.
- Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.
- Workplace performance effects from chronic depression and its treatment.
- Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia.
- Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
- Calculating the workplace cost of chronic disease.
- Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group.
- A telehealth nursing intervention reduces hospitalizations in children with complex health conditions.
- A cost-benefit analysis of a mandatory premarital rubella-antibody screening program.
Schools
Harvard Medical School
Doctors Specialties
- Internal Medicine
- Pathology
Accepted Insurances
Education
-
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Beth Israel Deaconess Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Martin C. Mihm Jr., MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mark A. Flomenbaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Madalon Meany, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter A. Hoenig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Steinbrook, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marguerite C. Roach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles S. Keevil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dea F. Angiolillo, MD
This Doctor is OpenDoctor Recommended.
|